(Q28084380)

title

Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's disease (English)

1 reference

1 reference

1 reference

cognitive dysfunction

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Maritza Sandoval-Rincón

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Michel Sáenz-Farret

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Federico Micheli

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Oscar Arias-Carrión

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

31 March 2015

1 reference

published in

Frontiers in Neurology

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

71

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

9 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Clinical diagnostic criteria for dementia associated with Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Changes in motor subtype and risk for incident dementia in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Prevalence and treatment of depression in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

A systematic review of prevalence studies of dementia in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Rivastigmine for dementia associated with Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Neuropsychological prediction of dementia in Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

2 June 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Memory and executive function impairment predict dementia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Differences in neuropathologic characteristics across the Lewy body dementia spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

What is a rational antidepressant treatment for major depression in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Combined beneficial effect of rasagiline on motor function and depression in de novo PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Assessment of cognition in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

The heterogeneity of cognitive symptoms in Parkinson's disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Comments on 'what is a rational antidepressant treatment for major depression in patients with Parkinson's disease?'.

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3389%2FFNEUR.2015.00071

Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Epidemiology of major depression in Belgian parkinsonian patients

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4379942

Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study

27 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25873910

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25873910

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3389/FNEUR.2015.00071

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25873910%20AND%20SRC:MED&resulttype=core&format=json